Journal article
Authors list: Geyer, Matthias; Mueller-Ladner, Ulf
Publication year: 2010
Journal: Arthritis Research and Therapy
Volume number: 12
Issue number: 4
ISSN: 1478-6354
eISSN: 1478-6362
Open access status: Gold
DOI Link: https://doi.org/10.1186/ar3102
Publisher: BioMed Central
Abstract:
Due to ongoing developments of novel agents in the field of biological pharmacotherapy, there are now more arrows available in clinicians' quivers for the treatment of rheumatic conditions. As a consequence, however, clear treatment strategies have to be defined in order to guarantee a qualitatively high and individually stage-adapted, state-of-the-art regimen for affected patients. This review summarizes recent evidence regarding the rationale of using different biological therapies to treat rheumatoid arthritis, the most common inflammatory joint disorder after activated osteoarthritis, and draws an actual picture of a possible standardized therapeutic algorithm without claiming exclusive appropriateness.
Citation Styles
Harvard Citation style: Geyer, M. and Mueller-Ladner, U. (2010) Rationale of using different biological therapies in rheumatoid arthritis, Arthritis Research and Therapy, 12(4), Article 214. https://doi.org/10.1186/ar3102
APA Citation style: Geyer, M., & Mueller-Ladner, U. (2010). Rationale of using different biological therapies in rheumatoid arthritis. Arthritis Research and Therapy. 12(4), Article 214. https://doi.org/10.1186/ar3102
Keywords
CHRONIC HEPATITIS-B; DISEASE-ACTIVITY; DOUBLE-BLIND; FACTOR ANTAGONISTS; INADEQUATE RESPONSE; INTERLEUKIN-6 RECEPTOR INHIBITION; MODIFYING ANTIRHEUMATIC DRUGS; RANDOMIZED-TRIAL
